Last reviewed: June 19, 2026
Last updated: June 19, 2026
Written by:
Jay Hastings,
CEO of PlexusDx
Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.
Medically reviewed by:
Jayden Lee, PharmD, EMBA
Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.
This article is part of the PlexusDx Education Hub — science-backed guidance on GLP-1 medications, metabolic health, and precision weight management.
A common source of confusion surrounds Ozempic and weight loss: Ozempic itself is not FDA-approved for weight management—it is approved exclusively for type 2 diabetes treatment. Wegovy, which contains the same active ingredient (semaglutide) at higher doses, received FDA clearance for chronic weight management in 2021. PlexusDx delivers compounded semaglutide from licensed 503A pharmacies to patients across all 50 states, offering personalized dosing without insurance requirements.
Ozempic vs. Wegovy: Understanding the FDA Distinction
Ozempic and Wegovy both contain semaglutide—a glucagon-like peptide-1 (GLP-1) receptor agonist—but serve different clinical purposes under FDA regulation. Ozempic dosing for diabetes typically tops out at 1 mg weekly, whereas Wegovy is approved at doses up to 2.4 mg weekly specifically for weight loss in adults with obesity or overweight status plus weight-related conditions. The regulatory separation exists because the FDA evaluated each formulation in distinct clinical trials designed for their respective indications. Many patients and providers use Ozempic off-label for weight loss, but this represents an unapproved use.
The distinction matters for insurance coverage, pharmacy stocking, and prescription labeling. Wegovy's FDA approval came after the STEP trial series demonstrated an average weight reduction of 15% over 68 weeks in participants treated with semaglutide 2.4 mg versus 2.4% in the placebo group. Ozempic prescriptions written for weight loss remain off-label, and many insurers decline to cover this use. PlexusDx compounded semaglutide injections bypass these insurance barriers entirely, offering a consistent flat monthly price regardless of the dose your provider titrates you to.
How Semaglutide Works for Weight Loss
Semaglutide activates GLP-1 receptors in the brain, particularly in regions that regulate appetite, satiety, and energy expenditure. When you take semaglutide, it slows gastric emptying—the rate at which food leaves your stomach—creating a lasting feeling of fullness that reduces overall calorie intake. The medication also enhances insulin secretion in response to meals and improves blood sugar stability, which helps prevent the hunger spikes that often follow blood glucose dips. These mechanisms combine to support sustainable weight loss without requiring extreme dietary restriction.
Clinical evidence shows semaglutide's effect on body weight is mediated through multiple peptide pathways. GLP1R signaling (the primary target) drives appetite suppression, while secondary effects on other receptors may influence metabolism and food reward processing. Each individual's response to semaglutide varies based on genetic factors—including variants in the GLP1R, GIPR, FTO, and MC4R genes—which affect how efficiently the body responds to the medication. The Precision Peptide Genetic Test offered by PlexusDx maps these 14 peptide pathways and 150+ genetic insights to help providers anticipate individual response patterns and optimize personalization.
Why Choose Compounded Semaglutide Over Brand-Name Options
Brand-name Ozempic and Wegovy face widespread supply shortages, high out-of-pocket costs for uninsured patients, and insurance barriers for off-label weight-loss use. Compounded semaglutide manufactured by licensed 503A pharmacies offers the same active pharmaceutical ingredient at a fraction of the cost. PlexusDx sources all semaglutide from licensed 503A compounding facilities—never from 503B facilities—ensuring pharmaceutical-grade quality, sterility, and potency testing. Patients across all 50 states access these injections without membership fees, insurance requirements, or prior-authorization delays.
PlexusDx compounded semaglutide injections start at $149 per month, a dramatic reduction from typical brand-name costs exceeding $900 monthly. The pricing model remains flat—your dose may need to go up during titration, but your price will not. HSA and FSA accounts cover compounded semaglutide, making the medication eligible for pre-tax health savings. Most patients receive their first shipment within 5–7 business days of completing their telehealth consultation and physician clearance.
Personalized Dosing and Genetic Testing With PlexusDx
PlexusDx tailors semaglutide therapy to your unique genetic profile through the Precision Peptide Genetic Test, a peptide-pathway genetic assessment that identifies how your body processes GLP-1 signaling. The test analyzes key variants including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313—genetic markers that influence appetite regulation, metabolism, and medication response. Patients with certain GLP1R variants, for instance, may benefit from earlier dose escalation, while those with specific FTO alleles often experience more pronounced metabolic improvements. This genetic insight empowers providers to design a dosing schedule that maximizes efficacy and minimizes unnecessary side effects.
The Precision Peptide Genetic Test is available as a $99 add-on after your first month of treatment, giving your PlexusDx provider a complete picture of your peptide biology. Unlike pharmacogenomic tests that predict drug metabolism by liver enzymes, this genetic assessment directly maps how your body's appetite and energy pathways respond to semaglutide. Combining genetic insights with your clinical response during the first month yields a highly personalized long-term treatment plan. PlexusDx's integrated approach to genetic testing and medication management represents a precision-health model unavailable through traditional pharmacy or insurance channels.
How Your Genetics Influence GLP-1 Response
Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month of treatment) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.
Access Personalized GLP-1 Care Through PlexusDx
PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection starts at $149/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.
Frequently Asked Questions
Is Ozempic actually approved by the FDA for weight loss?
No. Ozempic carries FDA approval for type 2 diabetes management only. Wegovy—a higher-dose semaglutide formulation—holds the FDA indication for chronic weight management. Many providers prescribe Ozempic off-label for weight loss, but this use lacks official regulatory approval. PlexusDx compounded semaglutide injections provide an accessible, regulated alternative at $149/month without insurance barriers.
How much weight loss should I expect from semaglutide?
Clinical trials show semaglutide produces an average weight reduction of 15% over one year in patients with obesity, compared to 2–3% with placebo. Individual results vary significantly based on genetics, diet adherence, physical activity, and baseline metabolic health. The Precision Peptide Genetic Test helps PlexusDx providers predict your likely response trajectory, allowing personalized dose adjustments and expectation-setting from the start.
What does PlexusDx compounded semaglutide cost compared to Wegovy?
PlexusDx compounded semaglutide injections start at $149 per month—typically 60–75% less expensive than brand-name Wegovy. Your dose may need to go up; your price will not. The medication is available in all 50 states, requires no insurance, and qualifies for HSA/FSA coverage. Most patients access their first shipment within 5–7 business days.
Are compounded semaglutide injections as safe as brand-name versions?
PlexusDx sources all compounded semaglutide from licensed 503A pharmacies, which maintain strict sterility, potency, and quality standards equivalent to pharmaceutical manufacturers. The active ingredient is identical to brand-name formulations. Side effects—primarily nausea, constipation, and appetite suppression—occur at similar rates. Your PlexusDx provider monitors your response and titrates your dose gradually to minimize adverse effects.
How does the Precision Peptide Genetic Test improve my weight-loss outcomes?
The test identifies your genetic variants in GLP1R, GIPR, FTO, and MC4R—genes controlling appetite signaling and metabolism. These insights help your provider predict whether you'll respond quickly to semaglutide, tolerate higher doses easily, or benefit from a slower titration. At $99 after your first treatment month, the genetic assessment enables truly personalized dosing, improving efficacy and reducing side effects compared to one-size-fits-all protocols.
Related Reading
Pricing and availability current as of June 2026. Compounded GLP-1 medications are not FDA-approved drug products; they are prepared by licensed compounding pharmacies under federal compounding regulations. Compounded semaglutide and tirzepatide are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro. This article is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting, stopping, or changing any medication.
Return to the PlexusDx Education Hub for more evidence-based resources on GLP-1 therapy, metabolic health, and personalized weight management.
Medical and Editorial Standards
Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.
Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.
Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.
Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.
Share:
What Happens If You Inject Zepbound Into Muscle?
Ozempic and AFib: Navigating Weight Loss with Heart Health Concerns